SCHEMBL30765885

SCHEMBL30765885

Cc1ccccc1-c1ncc(N[C@H](C)c2ccc3oc4ccccc4c3c2)c(=O)n1CC(=O)NCc1cc2cnccc2[nH]1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.34
F2 P00734 3/20 0.34
NAMPT P43490 1/20 0.33
F3 P13726 4/20 0.33
ALDH1A1 P00352 2/20 0.32
POLB P06746 2/20 0.32
NTRK1 P04629 1/20 0.32
AVPR1B P47901 1/20 0.32
THRB P10828 1/20 0.32
KDM4E B2RXH2 1/20 0.32
HCRTR1 O43613 1/20 0.32
USP2 O75604 1/20 0.32
GAA P10253 1/20 0.32
TSHR P16473 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
F10 P00742 1/20 0.31
PRSS1 P07477 1/20 0.31
PRSS2 P07478 1/20 0.31
PRSS3 P35030 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765543 0.92 ELANE (0.39) MAPK1F2F3NTRK1CMA1
SCHEMBL30765516 0.91 NTRK1 (0.35) MAPK1F2F3ALDH1A1NTRK1
SCHEMBL30765595 0.90 F3 (0.35) MAPK1F2F3ALDH1A1PRSS1
SCHEMBL30765625 0.89 F2 (0.36) MAPK1F2F3ALDH1A1KDM4E
SCHEMBL30765642 0.89 MAPK1 (0.35) MAPK1F2NAMPTF3ALDH1A1
SCHEMBL30766011 0.89 CMA1 (0.33) MAPK1F2ALDH1A1NTRK1KDM4E
SCHEMBL30765565 0.88 F3 (0.36) MAPK1F2F3NTRK1F10
SCHEMBL30765829 0.87 F3 (0.34) MAPK1F2F3ALDH1A1NTRK1
SCHEMBL30765871 0.87 F2 (0.36) MAPK1F2NAMPTF3ALDH1A1
SCHEMBL31558497 0.87 F2 (0.35) MAPK1F2NAMPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed